Next Article in Journal
Disparities of Health Service for the Poor in the Coastal Area: Does Universal Health Coverage Reduce Disparities?
Previous Article in Journal
Data Collection Infrastructure for Patient Outcomes in the UK—Opportunities and Challenges for Cell and Gene Therapies Launching
 
 
Journal of Market Access & Health Policy (JMAHP) is published by MDPI from Volume 12 Issue 1 (2024). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Taylor & Francis.
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Meta-Analysis of Real-World Evidence Comparing Non-Vitamin K Antagonist Oral Anticoagulants with Vitamin K Antagonists for the Treatment of Patients with Non-Valvular Atrial Fibrillation

1
School of Pharmacy, University of Connecticut, Storrs, CT, USA
2
Health Economist, Bayer AG, Berlin, Germany
3
Cardiologie, Centre Hospitalier Universitaire Trousseau et Université François Rabelais, Tours, France
4
LEDa-LEGOS, Université Paris-Dauphine, PSL ResearchUniversity, Paris, France
5
HEOR CV, Bayer Plc, Reading, UK
6
Faculty of Medicine, University of Aix-Marseille, Marseille, France
7
HEOR Department, HTA Team, Creativ-Ceutical, Paris, France
8
HEOR Department, Evidence Synthesis Team, Creativ-Ceutical, London, UK
9
HEHTA, University of Glasgow, Glasgow, UK
*
Author to whom correspondence should be addressed.
J. Mark. Access Health Policy 2019, 7(1), 1574541; https://doi.org/10.1080/20016689.2019.1574541
Submission received: 4 September 2018 / Revised: 16 January 2019 / Accepted: 18 January 2019 / Published: 4 February 2019

Abstract

Introduction: Numerous real-world studies have compared non-vitamin K antagonist oral anticoagulants (NOACs) with vitamin K antagonists (VKAs) in patients with non-valvular atrial fibrillation (NVAF). A meta-analysis was performed to synthesize the available evidence. Methods: Systematic searches were performed through 12/2016 to identify non-randomized NVAF studies comparing NOACs with VKAs, and reporting effectiveness, safety, or persistence. Results: Of 562 citations identified, 49, 79, and 18 compared rivaroxaban, dabigatran, and apixaban, respectively, with VKAs and were included. Compared with VKAs, rivaroxaban was associated with a reduced risk of ischemic stroke (IS) (hazard ratio [HR] = 0.83, 95% confidence interval [CI] = 0.75–0.93), intracranial haemorrhage (ICH) (HR = 0.69, 95% CI = 0.52–0.90), and non-persistence (HR = 0.62, 95% CI = 0.60–0.65). Dabigatran was associated with a significantly lower risk of IS (HR = 0.80, 95% CI = 0.65–0.98) and ICH (HR = 0.45, 95% CI = 0.36–0.58), but not for non-persistence (HR = 0.91, 95% CI = 0.53–1.55), compared with VKAs. Apixaban was associated with a lower risk of ICH than VKAs (HR = 0.41, 95% CI = 0.28–0.60), but was not different to VKAs in terms of IS (HR = 1.01, 95% CI = 0.87–1.17) or non-persistence (HR = 1.08, 95% CI = 0.81–1.45). Conclusion: NOACs appear to be at least as effective and safe as VKAs for stroke prevention in patients with NVAF.
Keywords: anticoagulation; non-valvular atrial fibrillation; non-vitamin K antagonist oral anticoagulants; real-world evidence; stroke prevention; meta-analysis anticoagulation; non-valvular atrial fibrillation; non-vitamin K antagonist oral anticoagulants; real-world evidence; stroke prevention; meta-analysis

Share and Cite

MDPI and ACS Style

Coleman, C.I.; Briere, J.-B.; Fauchier, L.; Levy, P.; Bowrin, K.; Toumi, M.; Millier, A.; Taieb, V.; Wu, O. Meta-Analysis of Real-World Evidence Comparing Non-Vitamin K Antagonist Oral Anticoagulants with Vitamin K Antagonists for the Treatment of Patients with Non-Valvular Atrial Fibrillation. J. Mark. Access Health Policy 2019, 7, 1574541. https://doi.org/10.1080/20016689.2019.1574541

AMA Style

Coleman CI, Briere J-B, Fauchier L, Levy P, Bowrin K, Toumi M, Millier A, Taieb V, Wu O. Meta-Analysis of Real-World Evidence Comparing Non-Vitamin K Antagonist Oral Anticoagulants with Vitamin K Antagonists for the Treatment of Patients with Non-Valvular Atrial Fibrillation. Journal of Market Access & Health Policy. 2019; 7(1):1574541. https://doi.org/10.1080/20016689.2019.1574541

Chicago/Turabian Style

Coleman, Craig I., Jean-Baptiste Briere, Laurent Fauchier, Pierre Levy, Kevin Bowrin, Mondher Toumi, Aurélie Millier, Vanessa Taieb, and Olivia Wu. 2019. "Meta-Analysis of Real-World Evidence Comparing Non-Vitamin K Antagonist Oral Anticoagulants with Vitamin K Antagonists for the Treatment of Patients with Non-Valvular Atrial Fibrillation" Journal of Market Access & Health Policy 7, no. 1: 1574541. https://doi.org/10.1080/20016689.2019.1574541

Article Metrics

Back to TopTop